|
ATP6V1B2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
1.320650E-03 |
| Normal-vs-Stage3 |
1.62447832963153E-12 |
| Normal-vs-Stage4 |
2.03725925018716E-13 |
| Stage1-vs-Stage2 |
1.544080E-02 |
| Stage1-vs-Stage3 |
4.373000E-01 |
| Stage1-vs-Stage4 |
9.094200E-02 |
| Stage2-vs-Stage3 |
9.903700E-03 |
| Stage2-vs-Stage4 |
2.258700E-03 |
| Stage3-vs-Stage4 |
3.270800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
2.09750000002007E-06 |
| Normal-vs-Asian |
9.90320048188664E-11 |
| Caucasian-vs-AfricanAmerican |
2.876200E-01 |
| Caucasian-vs-Asian |
4.962400E-01 |
| AfricanAmerican-vs-Asian |
6.435000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.36557432028894E-14 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
1.646430E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(61-80Yrs) |
7.37749972223867E-10 |
| Normal-vs-Age(81-100Yrs) |
1.361550E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.198000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.819600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.345600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.406200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.124000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.162400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.304100E-02 |
| Classical-VS-Follicular |
1.7643664307343E-12 |
| Classical-VS-Other |
9.847600E-02 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.09100000034168E-07 |
| Tall-VS-Other |
1.707990E-02 |
| Tall-VS-Normal |
3.83648668389469E-12 |
| Follicular-VS-Other |
5.003200E-01 |
| Follicular-VS-Normal |
8.118300E-03 |
| Other-VS-Normal |
1.522630E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.64468438867971E-12 |
| Normal-vs-N1 |
6.28530005819528E-10 |
| N0-vs-N1 |
7.813700E-02 |
|
|
